Dimtruzic 240 mg Kapsułki dojelitowe, twarde Ba Lan - Tiếng Ba Lan - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

dimtruzic 240 mg kapsułki dojelitowe, twarde

sandoz gmbh - dimethylis fumaras - kapsułki dojelitowe, twarde - 240 mg

Dimtruzic 120 mg Kapsułki dojelitowe, twarde Ba Lan - Tiếng Ba Lan - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

dimtruzic 120 mg kapsułki dojelitowe, twarde

sandoz gmbh - dimethylis fumaras - kapsułki dojelitowe, twarde - 120 mg

Fampridine Zentiva 10 mg Tabletka o przedłużonym uwalnianiu Ba Lan - Tiếng Ba Lan - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

fampridine zentiva 10 mg tabletka o przedłużonym uwalnianiu

zentiva, k.s. - fampridinum - tabletka o przedłużonym uwalnianiu - 10 mg

Dimethyl fumarate Teva Liên Minh Châu Âu - Tiếng Ba Lan - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - fumaran dimetylu - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Accord Liên Minh Châu Âu - Tiếng Ba Lan - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - fumaran dimetylu - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Tyruko Liên Minh Châu Âu - Tiếng Ba Lan - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.